Loading...
•
Dec 31, 2021
Cytek Biosciences Q4 2021 Earnings Report
Cytek Biosciences reported a revenue increase of 27% for the fourth quarter of 2021 compared to the same period in 2020 and expanded its installed base to 1,110 instruments.
Key Takeaways
Cytek Biosciences reported a strong fourth quarter, with a 27% increase in revenue compared to the previous year. The company also expanded its installed instrument base and enhanced its reagent portfolio through acquisitions and product launches.
Total revenue was $38.9 million for the fourth quarter, a 27% increase year-over-year.
Expanded the installed base to 1,110 instruments, with 140 instrument placements during the fourth quarter.
Closed the acquisition of Tonbo Biosciences’ reagents business.
Opened a new facility in Fremont, California, tripling previous manufacturing capacity.
Revenue by Segment
Forward Guidance
Cytek Biosciences expects full year 2022 revenue to be in the range of $160 million to $168 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...